Holds one active US DMF and one valid CEP for tamsulosin, filing since 2006. Its GMP is recognised in 14 markets.
Holds 2 active US DMFs and 2 valid CEPs for tamsulosin, filing since 2016. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.
Holds one active US DMF and one valid CEP for tamsulosin, filing since 2004. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 25 markets.
Holds 4 active US DMFs and 2 valid CEPs for tamsulosin, filing since 2006. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs and one valid CEP for tamsulosin, filing since 2022. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one active US DMF for tamsulosin, filing since 2005. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Holds one active US DMF for tamsulosin, filing since 2009. Its 2023 FDA inspection closed as VAI, and its GMP is recognised in 7 markets.
Holds one valid CEP for tamsulosin, filing since 2023. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 6 markets.
Holds one active US DMF for tamsulosin, filing since 2004. Its GMP is recognised in 13 markets.
Holds one valid CEP for tamsulosin, filing since 2024. Its 2026 FDA inspection closed as VAI, and its GMP is recognised in 13 markets.
Holds 4 valid CEPs for tamsulosin, filing since 2018. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds one active US DMF and one valid CEP for tamsulosin, filing since 2006. Its 2025 FDA inspection closed as VAI.
Holds one active US DMF for tamsulosin, filing since 2005. Its 2022 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs for tamsulosin, filing since 2022. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one active US DMF for tamsulosin, filing since 2007. Its 2023 FDA inspection closed as VAI.
Holds one valid CEP for tamsulosin, filing since 2025. Its 2023 FDA inspection closed as NAI.
Registered with SFDA (Saudi Arabia) for tamsulosin. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 6 markets.
Holds one valid CEP for tamsulosin, filing since 2026. Its GMP is recognised in 11 markets.
Holds one valid CEP for tamsulosin, filing since 2018. Its GMP is recognised in 1 market.
Holds one active US DMF for tamsulosin, filing since 2010.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free| Year | Median | Exporters |
|---|---|---|
| 2025 | $123.76 | 64 |
| 2024 | $175.00 | 68 |
| 2023 | $120.00 | 81 |
| 2022 | $122.87 | 65 |
US dollars per kilogram, customs export unit values.